CARIS LIFE SCIENCES, INC. Operating Income
CARIS LIFE SCIENCES, INC. (CAI) reported Operating Income of $26.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- CARIS LIFE SCIENCES, INC. operating income (loss) for the quarter ending 2026-06-30 was $26.93M.
- CARIS LIFE SCIENCES, INC. operating income (loss) for the quarter ending 2026-03-31 was $5.28M.
- CARIS LIFE SCIENCES, INC. operating income (loss) for the quarter ending 2025-12-31 was $88.41M.
- CARIS LIFE SCIENCES, INC. operating income (loss) for the quarter ending 2025-09-30 was $32.64M.
- CARIS LIFE SCIENCES, INC. operating income (loss) for fiscal 2025 was $45.11M.
- CARIS LIFE SCIENCES, INC. operating income (loss) for fiscal 2024 was -$257.12M.
- CARIS LIFE SCIENCES, INC. operating income (loss) for fiscal 2023 was -$319.55M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.93M 10-Q · filed 2026-08-05 | $32.21M 10-Q · filed 2026-08-05 | $120.62M derived: sum of 3 quarters · filed 2026-08-05 | $153.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $5.28M 10-Q · filed 2026-05-08 | $93.69M derived: sum of 2 quarters · filed 2026-05-08 | $126.33M derived: sum of 3 quarters · filed 2026-05-08 | $108.35M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $88.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $121.05M derived: sum of 2 quarters · filed 2026-03-03 | $103.06M derived: sum of 3 quarters · filed 2026-08-05 | $45.11M 10-K · filed 2026-03-03 |
| 2025-09-30 | $32.64M 10-Q · filed 2025-11-05 | $14.65M derived: sum of 2 quarters · filed 2026-08-05 | -$43.30M 10-Q · filed 2025-11-05 | -$80.34M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$17.99M 10-Q · filed 2026-08-05 | -$75.94M 10-Q · filed 2026-08-05 | -$112.99M derived: sum of 3 quarters · filed 2026-08-05 | -$173.83M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$57.95M 10-Q · filed 2026-05-08 | -$95.00M derived: sum of 2 quarters · filed 2026-05-08 | -$155.84M derived: sum of 3 quarters · filed 2026-05-08 | -$222.85M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$37.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$97.89M derived: sum of 2 quarters · filed 2026-03-03 | -$164.90M derived: sum of 3 quarters · filed 2026-03-03 | -$257.12M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$60.84M 10-Q · filed 2025-11-05 | -$127.85M derived: sum of 2 quarters · filed 2025-11-05 | -$220.08M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | -$67.01M 10-Q · filed 2025-08-12 | -$159.23M 10-Q · filed 2025-08-12 | ||
| 2023-12-31 | -$319.55M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |